A new approach that detects breast cancer vasculature is making an appearance at the 2010 RSNA meeting. The method, called high spectral and spatial resolution, or HiSS, uses water to detect tumor blood vessels without contrast.
A new approach that detects breast cancer vasculature is making an appearance at the 2010 RSNA meeting. The method, called high spectral and spatial resolution, or HiSS, uses water to detect tumor blood vessels without contrast.
Two papers on the topic have been presented. The first identified blood vessels and distinguished between malignant and benign breast lesions. The second compared precontrast HiSS MRI with conventional contrast-enhanced MRI for classifying malignant and benign breast lesions.
HiSS is a type of spectroscopic imaging that does not visualize metabolites. Instead it separates the water and fat signals, allowing elimination of the fat signal in postprocessing.
In the first study Abbie Wood, a physics graduate student at the University of Chicago, and colleagues determined anatomic and physiologic features that cause local magnetic susceptibility gradients to produce partially resolved off-peak components in the water resonance. The off-peak components include paramagnetic deoxyhemoglobin, calcifications, and hemosiderin. Cancers tend to have elevated levels of deoxyhemoglobin, and this effect is detectable in vivo. Wood and colleagues evaluated off-peak components of the water resonance as a marker for malignant breast lesions.
In 24 patients, the investigators found 16 invasive cancers and eight benign enhancing breast lesions. Patients were imaged with MRI while HiSS data were acquired using an echoplanar spectroscopic imaging (EPSI) sequence with 1 x 1 x 2-mm3 voxels and a spectral resolution of 2.5 Hz. Dynamic-contrast–enhanced MR images were acquired with temporal resolution of one minute. Images were generated from the frequency difference between the peak of the water resonance and the largest off-peak non-Lorentzian spectral component.
The researchers found frequencies of off-peak components were significantly larger in malignant lesions than in benign lesions. Frequencies of off-peak components were similar in benign lesions and normal parenchyma. They also found contrast media washout kinetics were significantly different in malignant and benign lesions. Contrast washout was detected in more of the malignant lesion pixels than in the benign lesion pixels.
“We found a noninvasive method of diagnosing breast lesions, which provides new functional information that could improve diagnostic accuracy when paired with dynamic-contrast–enhanced MR results,” Wood said.
Wood was awarded the trainee research prize for her abstract.
The second paper, presented by Milica Medved, Ph.D., an assistant professor at the University of Chicago, found precontrast HiSS images performed as well as conventional postcontrast images in differentiating benign and malignant lesions.
“This is of high significance for the large number of patients for whom contrast agent administration is contraindicated due to poor kidney function or allergic reactions,” Medved said. “In addition, precontrast HiSS imaging could be used for improved assessment of lesion morphology without blurring artifacts due to contrast agent administration.”
AI Facilitates Nearly 83 Percent Improvement in Turnaround Time for Fracture X-Rays
December 19th 2023In addition to offering a 98.5 percent sensitivity rate in diagnosing fractures on X-ray, an emerging artificial intelligence (AI) software reportedly helped reduce mean turnaround time on X-ray fracture diagnosis from 48 hours to 8.3 hours, according to new research presented at the Radiological Society of North America (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can an Emerging PET Radiotracer Enhance Detection of Prostate Cancer Recurrence?
December 14th 2023The use of 68Ga-RM2 PET/MRI demonstrated a 35 percent higher sensitivity rate than MRI alone for the diagnosis of biochemical recurrence of prostate cancer, according to research recently presented at the Radiological Society of North America (RSNA) conference.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
Can AI Improve Detection of Extraprostatic Extension on MRI?
December 4th 2023Utilizing a deep learning-based AI algorithm to differentiate between diagnostic and non-diagnostic quality of prostate MRI facilitated a 10 percent higher specificity rate for diagnosing extraprostatic extension on multiparametric MRI, according to research presented at the recent RSNA conference.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.